| | No. (%) of Patients |
|---|
| Age (yr) |
| Median | 80 |
| Range | 75–87 |
| Sex |
| Male | 19 (63.3) |
| Female | 11 (36.7) |
| Karnofsky performance status |
| 100, 90 | 2 (6.7) |
| 80, 70 | 17 (56.7) |
| 60, 50 | 11 (36.7) |
| Extent of resection |
| Total resection | 8 (26.7) |
| Subtotal resection | 3 (10) |
| Partial resection | 7 (23.3) |
| Biopsy | 12 (40) |
| Chemotherapy |
| Temozolomide | 20 (66.7) |
| Temozolomide/Bevacizumab | 10 (33.3) |
| Adjuvant Temozolomide cycles (n) |
| Median | 5 |
| Range | 0–20 |
| Use of corticosteroid |
| Yes | 6 (20) |
| No | 24 (80) |
| Treatment after tumor recurrence |
| Best supportive care | 21 (70) |
| Bev | 5 (16.7) |
| Surgery followed by Temozolomide | 1 (3.3) |
| Temozolomide | 1 (3.3) |
| No recurrence | 2 (6.7) |
| MGMT promoter status |
| High | 11 (36.7) |
| Low | 16 (53.3) |
| N/A | 3 (10) |
| IDH 1/2 status |
| Wild-type | 29 (96.7) |
| Mutant | 0 |
| N/A | 1 (3.3) |
- IDH Isocitrate dehydrogenase, MGMT O6-methylguanine DNA methyltransferase, N/A Not available
